RDY's Q4 Results in Detail Dr. Reddy's reported revenues under three segments — Global Generics, Pharmaceutical Services & Active Ingredients (PSAI) and Others. Global Generics revenues totaled INR 65.8 billion, down 13% year over year. The decrease was mainly due to lower North America generics sales, partly offset by broad-based growth across key markets supported by favorable foreign exchange movements. Key Takeaways Dr. Reddy's Laboratories Limited (RDY) reported fourth-quarter fiscal 2026 adjusted earn ...

Alok Dalal - Analyst Ashutosh Jha - Analyst Bino Pathiparampil - Analyst Damayanti Kerai - Analyst Lavanya Tottala - Analyst Neha Manpuria - Analyst Saion Mukherjee - Analyst Siddharth Nigande - Analyst Surya Patra - Analyst Tushar Manudhane - Analyst Vishal Manchanda - Analyst Vivek Agarwal - Analyst Aishwarya Tripathy Our Chief Executive Officer, and Mr. M.V. Narasimhan, our Chief Financial Officer. Our quarterly financial results have been published earlier today and are available on our website for your ...